One Goal, Four Paths: Comparing COVID-19 Vaccine Pivotal Trial Protocols
Executive Summary
Phase III protocols for COVID-19 vaccine candidates from Pfizer/BioNTech, Moderna, AstraZeneca and Johnson & Johnson are similar – but definitely not the same.
You may also be interested in...
The Race To Develop A COVID-19 Vaccine: The Finish Line Approaches
Updated: a graphic tracker of key developments from the leading vaccine candidates.
US FDA’s Two-Month Safety Window For COVID Vaccines Based On Adverse Events In Other Products
In remarks fleshing out the ‘EUA Plus’ guidance before it became a political football, Operation Warp Speed’s Slaoui said that an FDA analysis concluded that 90% of adverse events related to vaccination take place within the first 42 days.
US FDA Expects COVID-19 Vaccines To Meet ‘EUA Plus’ Standards, Marks Says
CBER director said that all the manufacturing data may not be available, but the safety and efficacy data needed for a BLA are expected before an emergency use authorization is granted.